Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: The French participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.

被引：1
|
作者：
Andre, Thierry
Bonnetain, Franck
Mineur, Laurent
Bennouna, Jaafar
Desrame, Jerome
Faroux, Roger
Dauba, Jerome
Vernerey, Dewi
Aissat, Nasredine
Louvet, Christophe
Lepere, Celine
Dupuis, Olivier Jean Marie
Becouarn, Yves
Mabro, May
Egreteau, Joelle
Bouche, Olivier
Deplanque, Gael
Ychou, Marc
De Gramont, Aimery
Taieb, Julien
机构：
[1] Hop St Antoine, APHP, Dept Med Oncol, Paris, France
[2] Univ Hosp Besancon, Dept Oncol, Methodol & Qual Life Unit, INSERM,UMR 1098, Besancon, France
[3] French Natl Platform Qual Life & Canc, Besancon, France
[4] Inst St Catherine, Avignon, France
[5] Inst Cancerol Ouest, Nantes, France
[6] Hop Prive Jean Mermoz, Lyon, France
[7] Ctr Hosp Dept Oudairies, La Roche Sur Yon, France
[8] Hop Layne, Dept Gastroenterol, Mt De Marsan, France
[9] CHRU Besancon, Methodol & Qual Life Oncol Unit, Besancon, France
[10] GERCOR, Paris, France
[11] Inst Mutualiste Montsouris, Paris, France
[12] Hop Europeen Georges Pompidou, Paris, France
[13] Clin Victor Hugo, Le Mans, France
[14] Inst Bergonie, Bordeaux, France
[15] Hop Foch, Suresnes, France
[16] Ctr Hosp Bretagne Sud, Lorient, France
[17] CHU Robert Debre, Reims, France
[18] CHU Vaudois, Med Oncol, Lausanne, Switzerland
[19] Inst Reg Canc Montpellier, Montpellier, France
[20] Franco British Inst, Levallois Perret, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.3500
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3500
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Adjuvant chemotherapy for stage III colon cancer patients
    Balakrishnan, L
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (11) : 1496 - 1496
  • [32] Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
    Yamazaki, K.
    Yamanaka, T.
    Shiozawa, M.
    Manaka, D.
    Kotaka, M.
    Gamoh, M.
    Shiomi, A.
    Makiyama, A.
    Munemoto, Y.
    Rikiyama, T.
    Fukunaga, M.
    Ueki, T.
    Shitara, K.
    Shinkai, H.
    Tanida, N.
    Oki, E.
    Sunami, E.
    Ohtsu, A.
    Maehara, Y.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2021, 32 (01) : 77 - 84
  • [33] Three Versus Six Months of Adjuvant Oxaliplatin-Containing Chemotherapy for Patients With Stage III Colorectal Cancer: A Contemporary Real-World Analysis
    Krishnan, Tharani
    Leung, Emily
    Vasconcelos, Joao Paulo Solar
    Lim, Howard
    Loree, Jonathan M.
    Davies, Janine
    Gill, Karamjit
    Gill, Sharlene
    JCO ONCOLOGY PRACTICE, 2025, 21 (03)
  • [34] Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysis
    Cohen, R.
    Raeisi, M.
    Chibaudel, B.
    Yothers, G.
    Goldberg, R. M.
    Bachet, J. -B
    Wolmark, N.
    Yoshino, T.
    Schmoll, H. -J
    Haller, D. G.
    Kerr, R.
    Lonardi, S.
    George, T. J.
    Shacham-Shmueli, E.
    Shi, Q.
    Andre, T.
    de Gramont, A.
    ESMO OPEN, 2025, 10 (03)
  • [35] Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials
    Gallois, Claire
    Shi, Qian
    Meyers, Jeffrey P.
    Iveson, Timothy
    Alberts, Steven R.
    De Gramont, Aimery
    Sobrero, Alberto F.
    Haller, Daniel G.
    Oki, Eiji
    Shields, Anthony Frank
    Kelly, Caroline
    Boukovinas, Ioannis
    Labianca, Roberto
    Sinicrope, Frank A.
    Sougklakos, Ioannis
    Yoshino, Takayuki
    Meyerhardt, Jeffrey A.
    Andre, Thierry
    Papamichail, Demetris
    Taieb, Julien
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [36] ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
    Baek, Moo-Jun
    ANNALS OF COLOPROCTOLOGY, 2015, 31 (03) : 81 - 81
  • [37] Palliative oxaliplatin-based chemotherapy after exposure to oxaliplatin in the adjuvant setting for colon cancer.
    Peixoto, Renata D'Alpino
    Kumar, Aalok
    Gill, Sharlene
    Lim, Howard John
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [38] Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer
    Kumar, Aalok
    Peixoto, Renata D.
    Kennecke, Hagen F.
    Renouf, Daniel J.
    Lim, Howard J.
    Gil, Sharlene
    Speers, Caroline H.
    Cheung, Winson Y.
    CLINICAL COLORECTAL CANCER, 2015, 14 (04) : 262 - 268
  • [39] Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer
    Brungs, Daniel
    Aghmesheh, Morteza
    de Souza, Paul
    Carolan, Martin
    Clingan, Philip
    Rose, June
    Ranson, Marie
    CLINICAL COLORECTAL CANCER, 2018, 17 (03) : E549 - E555
  • [40] Long-term effect of peripheral sensory neuropathy (PSN) of 3 or 6 months oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: ACHIEVE as part of the IDEA collaboration
    Takeuchi, S.
    Yoshino, T.
    Yamanaka, T.
    Kotaka, M.
    Manaka, D.
    Eto, T.
    Hasegawa, J.
    Takagane, A.
    Nakamura, M.
    Kato, T.
    Munemoto, Y.
    Bando, H.
    Taniguchi, H.
    Gamoh, M.
    Shiozawa, M.
    Saji, S.
    Maehara, Y.
    Mizushima, T.
    Ohtsu, A.
    Mori, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 110 - 110
12345